title: Ribozyme therapeutics.
authors.affiliation: Argonex Inc., Charlottesville, VA 22901, USA. apersidis@argonex.com
authors.forename: A
authors.initials: A
authors.lastname: Persidis
mesh_terms: D001851:Bone Diseases, Metabolic / Q000628:therapy; D002318:Cardiovascular Diseases / Q000628:therapy; D003362:Cost-Benefit Analysis; D003920:Diabetes Mellitus / Q000628:therapy; D015195:Drug Design; D015316:Genetic Therapy / Q000191:economics / Q000639:trends*; D015658:HIV Infections / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use*; D016337:RNA, Catalytic / Q000737:chemistry / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism
chemical_list: D011500:Protein Synthesis Inhibitors; D016337:RNA, Catalytic; D012333:RNA, Messenger